Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 253 of 5804
-
AI-Powered screening aims to catch lung cancer early in veterans
Prevention Recruiting nowLung cancer is responsible for more deaths in the United States than breast, prostate and colon cancer combined and is the number one cancer killer of Veterans. This is because lung cancer is usually diagnosed when the disease has spread, and cure is less likely. Lung cancer scre…
Phase: NA • Sponsor: VA Office of Research and Development • Aim: Prevention
Last updated Jun 28, 2026 00:00 UTC
-
New drug trial aims to tame seizures in rare childhood disorder
Disease control Not yet recruitingThis study will assess the efficacy, safety, and tolerability of ganaxolone (GNX) compared with placebo (PBO) as adjunctive therapy to the participant's standard anti-epileptic medication for the treatment of seizures in pediatric patients from 6 months to less than 2 years old w…
Phase: PHASE3 • Sponsor: Immedica Pharma AB • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New drug cocktail aims to outsmart lung cancer resistance
Disease control Not yet recruitingProtocol Title A Study to Evaluate ANS014004 in Combination with EGFR-TKI in Patients with EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer The main purpose of this research study is to Find a safe and tolerable dose of two investigational drugs…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Pearl Biotechnology Limited Liability Company • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New drug cocktail aims to tame deadly transplant complication
Disease control Recruiting nowThis is an open label, non-randomized, multicenter, pilot, dose expansion study of low dose post-transplant cyclophosphamide (25 mg/kg on Days +3 and +4)/tacrolimus/ruxolitinib in the setting of myeloablative conditioning (MAC) allogeneic peripheral blood stem cell transplantatio…
Phase: PHASE2 • Sponsor: Hannah Choe, MD • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New combo therapy aims to treat leukemia without harsh chemo
Disease control Not yet recruitingThe purpose of this study is to find out whether combining inotuzumab and blinatumomab is a safe and effective treatment for participants with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL).
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Can CBD boost clozapine for Treatment-Resistant psychosis?
Disease control Not yet recruitingThe purpose of this trial is: * To investigate whether the response to clozapine treatment can be enhanced by adding cannabidiol (CBD), compared to placebo, in treatment resistant psychosis patients. * To confirm the safety of CBD in people with psychosis. The trial is a random…
Phase: PHASE3 • Sponsor: University of Oxford • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New hope for rare kidney cancer: drug trial targets tough tumors
Disease control Not yet recruitingTo learn if sacituzumab tirumotecan can help to control advanced or metastatic SMARCB1-deficient RMC in patients whose disease has progressed after receiving at least 1 treatment.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New combo therapy aims to shrink advanced liver and kidney tumors
Disease control Not yet recruitingThis is a Phase II study being done at several hospitals without using a placebo. It will look at how safe and tolerable the drug WGI-0301 is when given together with nivolumab, how the body processes and responds to WGI-0301, and whether this combination shows early signs of wor…
Phase: PHASE2 • Sponsor: Zhejiang Haichang Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New drug cocktail aims to shrink liver tumors for surgery
Disease control Not yet recruitingThis study is a single-center, prospective, randomized, single-arm phase II clinical trial designed to evaluate the safety and efficacy of FULIRI chemotherapy regimen combined with targeted therapy (bevacizumab/cetuximab) as first-line conversion therapy for colorectal cancer wit…
Phase: PHASE2 • Sponsor: Zhongnan Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug cocktail aims to shrink kidney tumors before surgery
Disease control Not yet recruitingThis study is designed to evaluate the efficacy of belzutifan in combination with pembrolizumab with or without lenvatinib in the neoadjuvant setting, followed by adjuvant pembrolizumab versus adjuvant pembrolizumab alone, as treatment for participants with intermediate-high and …
Phase: PHASE2 • Sponsor: Vall d'Hebron Institute of Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug combo aims to shrink stomach tumors before surgery
Disease control Not yet recruitingStudy Background 1. Clinical Rationale and Unmet Medical Need Gastric cancer is the 5th most common malignancy and the 3rd leading cause of cancer death worldwide. China accounts for \>40% of global new cases, with nearly 90% of patients diagnosed at locally advanced stages and …
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug cocktail aims to tackle myeloma that resists CAR-T therapy
Disease control Not yet recruitingThe BELAMI trial is an open label, multicenter, phase 2 study for patients with MM who relapsed following BCMA-directed CAR-T cells or bispecific antibodies with a Phase Ib Safety run-in. The primary hypothesis of this study is that a combination of ADC targeting BCMA and CELMoD…
Phase: PHASE1, PHASE2 • Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cocktail targets genetic weakness in advanced breast cancer
Disease control Not yet recruitingThis is a prospective, multicenter, open-label, single-arm phase II investigator-initiated study designed to evaluate the efficacy and safety of inavolisib in combination with ribociclib and fulvestrant as first-line treatment in Chinese patients with PIK3CA-mutant, hormone recep…
Phase: PHASE2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug BHV-1400 aims to protect kidneys in IgA nephropathy
Disease control Not yet recruitingThe purpose of this study is to determine if BHV-1400 is effective and safe in the treatment of IgA Nephropathy. Participants will be randomized in a 2:1 ratio to receive either BHV-1400 or placebo.
Phase: PHASE3 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Experimental gene therapy targets rare metabolic disease in toddlers
Disease control Recruiting nowPropionic acidemia is a genetic metabolic disorder characterized by metabolic acidosis, ketosis, vomiting, lethargy, cognitive impairment, and risk of death. It results from loss of function of the mitochondrial enzyme propionyl-CoA carboxylase and can be due to disease-causing v…
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Engineered immune cells take aim at two cancer targets
Disease control Recruiting nowThe purpose of this study is to assess the feasibility, safety and efficacy of anti-PSMA/CD70 bi-specific CAR-T cell therapy in patients with CD70 and PSMA positive malignancies. Another goal of the study is to learn more about the function of the PSMA/CD70 bi-specific CAR-T cell…
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Immune cell therapy takes on HPV
Disease control Recruiting nowThe purpose of this clinical trial is to evaluate the safety and efficacy of IV-infused autologous or allogenic HPV-CTLs.
Phase: PHASE1, PHASE2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Promising PTSD drug moves to Long-Term safety study
Disease control ENROLLING_BY_INVITATIONThis study is evaluating the long-term safety and efficacy of TSND-201 in adults with PTSD. Participants that have completed a double-blind clinical trial with TNSD-201 for PTSD will be invited to participate in this open-label extension trial. Each participant will be able to r…
Phase: PHASE3 • Sponsor: Transcend Therapeutics • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Can a natural supplement shield the aging brain from Surgery's mental fog?
Disease control Not yet recruitingPostoperative Cognitive Dysfunction (POCD) is a common complication after surgery, particularly among older adults. It is characterized by cognitive impairment, reduced functional independence, and decreased quality of life. Growing evidence suggests that neuroinflammation plays …
Phase: NA • Sponsor: Fondazione IRCCS San Gerardo dei Tintori • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Could CBD oil lift the fog of Treatment-Resistant depression?
Symptom relief Recruiting nowMajor depressive disorder is one of the leading causes of disability worldwide, and a substantial proportion of patients do not achieve adequate improvement with conventional antidepressant treatments. Cannabidiol (CBD), a non-intoxicating cannabinoid derived from Cannabis sativa…
Phase: PHASE1, PHASE2 • Sponsor: Universidade do Sul de Santa Catarina • Aim: Symptom relief
Last updated Jul 12, 2026 00:00 UTC